Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial

被引：4

作者：

Ventura-Enriquez, Yanet ^{[1
]}

Cabello-Gutierrez, Carlos ^{[2
]}

Augusto Perez-Calatayud, Angel ^{[3
]}

Cortina-De la Rosa, Evelyn ^{[1
,4
]}

Javier Fareli-Gonzalez, Christian ^{[5
]}

Castillo-Juarez, Paola ^{[2
,6
]}

Pena-Perez Carlos, Alberto ^{[7
]}

Omar Zavaleta-Martinez, Eli ^{[7
]}

Diaz-Padilla, Elizabeth ^{[1
,8
]}

Murrieta, Sandra ^{[1
]}

Deyanira Alvarez-Jimenez, Violeta ^{[9
]}

Diaz Ponce-Medrano, Juan Alberto ^{[10
]}

Casillas-Suarez, Catalina ^{[3
]}

Angelica Ocampo-Ocampo, Maria ^{[3
]}

Vargas-De-Leon, Cruz ^{[11
,12
]}

Fernandez-Sanchez, Veronica ^{[1
,11
,13
]}

机构：

[1] Ctr Med Naval CEMENAV, Banco Sangre, Ciudad De Mexico 04470, Mexico

[2] Inst Nacl Enfermedades Resp INER, Dept Invest Virol & Micol, Ciudad De Mexico 14080, Mexico

[3] Hosp Gen Mexico Dr Eduardo Liceaga, Div Med Crit, Ciudad De Mexico 06720, Mexico

[4] Inst Nacl Cardiol Ignacio Chavez, Dept Hematol, Ciudad De Mexico 14080, Mexico

[5] Natl Ctr Technol Excellence Hlth, Guias Pract Clin, Ciudad De Mexico 06600, Mexico

[6] Inst Politecn Nacl IPN, Dept Microbiol, Escuela Nacl Ciencias Biol, Ciudad De Mexico 11340, Mexico

[7] Ctr Med Naval CEMENAV, Unidad Cuidados Intensivos, Ciudad De Mexico 04470, Mexico

[8] UNAM, Fac Quim, Ciudad De Mexico 04510, Mexico

[9] Ctr Med Naval CEMENAV, Biol Mol & BSL 3, Ciudad De Mexico 04470, Mexico

[10] Ctr Med Naval CEMENAV, Direcc Gen, Ciudad De Mexico 04470, Mexico

[11] Hosp Juarez Mexico, Div Invest, Ciudad De Mexico 07760, Mexico

[12] Inst Politecn Nacl IPN, Escuela Super Med, Secc Estudios Invest & Posgrad, Ciudad De Mexico 11340, Mexico

[13] Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala FES Iztacala, Ciudad De Mexico 54090, Mexico

来源：

LIFE-BASEL | 2022年 / 12卷 / 11期

关键词：

convalescent plasma treatment; COVID-19; neutralizing antibodies; SARS-CoV-2; MORTALITY;

D O I：

10.3390/life12111767

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. This study evaluated the safety and efficacy of the use of donor CP for COVID-19. Material and methods: A double-blind, randomized controlled clinical trial was conducted from May to October 2020. Thirty-nine participants with moderate (II) and severe (III) stages of COVID-19 confirmed by RT-PCR were included. The study randomization rate was set at 3:1. CPs were chosen for application with a neutralizing antibody titer of >= 1:32. Results: We observed a significantly lower 21-day post-transfusion mortality HR: 0.17 (95.0% CI [0.07-0.45, p < 0.001]) in the group receiving CP compared with the control group; protective units (PU) in the group receiving convalescent plasma after seven days were significantly higher (512 (32-16,384) vs. 96 (32-256), p = 0.01); the PAO(2)/FIO2 index showed a significant improvement in the group receiving CP (251.01 (109.4) vs. 109.2 (62.4), p < 0.001, in the control group). Conclusion: CP is safe and effective, as it decreased mortality in the CP group compared with the control group.

引用

页数：13

共 27 条

[1] Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study [J].

Abolghasemi, Hassan ;

Eshghi, Peyman ;

Cheraghali, Abdol Majid ;

Fooladi, Abbas Ali Imani ;

Moghaddam, Farzaneh Bolouki ;

Imanizadeh, Sina ;

Maleki, Matin Moeini ;

Ranjkesh, Mohammad ;

Rezapour, Mohammad ;

Bahramifar, Ali ;

Einollahi, Behzad ;

Hosseini, Mohammad Javad ;

Jafari, Nematollah Joneidi ;

Nikpouraghdam, Mohamad ;

Sadri, Nariman ;

Tazik, Mokhtar ;

Sali, Shanaz ;

Okati, Shamsi ;

Askari, Elham ;

Tabarsi, Payam ;

Aslani, Jafar ;

Sharifipour, Ehsan ;

Jarahzadeh, Mohammad Hossein ;

Khodakarim, Nastaran ;

Salesi, Mahmood ;

Jafari, Ramezan ;

Shahverdi, Samira .

TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (05)

[2] Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [J].

Agarwal, Anup ;

Mukherjee, Aparna ;

Kumar, Gunjan ;

Chatterjee, Pranab ;

Bhatnagar, Tarun ;

Malhotra, Pankaj .

BMJ-BRITISH MEDICAL JOURNAL, 2020, 371

[3]

[Anonymous], 2021, RECOVERY STATEMENT

[4]

[Anonymous], CONCOR 1 RANDOMIZED

[5]

[Anonymous], 2021, REMAP CAP STATEMENT

[6] Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol [J].

Arabi, Yaseen ;

Balkhy, Hanan ;

Hajeer, Ali H. ;

Bouchama, Abderrezak ;

Hayden, Frederick G. ;

Al-Omari, Awad ;

Al-Hameed, Fahad M. ;

Taha, Yusri ;

Shindo, Nahoko ;

Whitehead, John ;

Merson, Laura ;

AlJohani, Sameera ;

Al-Khairy, Khalid ;

Carson, Gail ;

Luke, Thomas C. ;

Hensley, Lisa ;

Al-Dawood, Abdulaziz ;

Al-Qahtani, Saad ;

Modjarrad, Kayvon ;

Sadat, Musharaf ;

Rohde, Gernot ;

Leport, Catherine ;

Fowler, Robert .

SPRINGERPLUS, 2015, 4 :1-8

[7]

Avendano-Sola C., 2020, CONVALESCENT PLASMA

[8]

Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]

[9]

Food and Drug Administration, COVID 19 CONV PLASM

[10] Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J].

Huang, Chaolin ;

Wang, Yeming ;

Li, Xingwang ;

Ren, Lili ;

Zhao, Jianping ;

Hu, Yi ;

Zhang, Li ;

Fan, Guohui ;

Xu, Jiuyang ;

Gu, Xiaoying ;

Cheng, Zhenshun ;

Yu, Ting ;

Xia, Jiaan ;

Wei, Yuan ;

Wu, Wenjuan ;

Xie, Xuelei ;

Yin, Wen ;

Li, Hui ;

Liu, Min ;

Xiao, Yan ;

Gao, Hong ;

Guo, Li ;

Xie, Jungang ;

Wang, Guangfa ;

Jiang, Rongmeng ;

Gao, Zhancheng ;

Jin, Qi ;

Wang, Jianwei ;

Cao, Bin .

LANCET, 2020, 395 (10223) :497-506

← 1 2 3 →